--- title: "Weekly Recap | Palantir Tech -14.58%, hitting a 60-day low" type: "News" locale: "en" url: "https://longbridge.com/en/news/306359781.md" description: "Palantir Tech fell 14.58% this week to close at $143.49, underperforming the S&P 500 by about 5.97 percentage points. The S&P 500 itself dropped 8.61%. The stock moved lower in a near one-way pullback, opening Monday at $165.76 and sliding through most sessions. It briefly stabilised on Tuesday and Wednesday, then accelerated lower on Thursday and again on Friday, touching $142.28 intraday — a 60-day low. Weekly volume totalled 108." datetime: "2026-11-21T07:09:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306359781.md) - [en](https://longbridge.com/en/news/306359781.md) - [zh-HK](https://longbridge.com/zh-HK/news/306359781.md) generator: "portal-rs" --- # Weekly Recap | Palantir Tech -14.58%, hitting a 60-day low ## The Week Palantir Tech (PLTR.US) fell 14.58% this week to close at $143.49, underperforming the S&P 500 by about 5.97 percentage points. The S&P 500 itself dropped 8.61%. The stock moved lower in a near one-way pullback, opening Monday at $165.76 and sliding through most sessions. It briefly stabilised on Tuesday and Wednesday, then accelerated lower on Thursday and again on Friday, touching $142.28 intraday — a 60-day low. Weekly volume totalled 108.3m shares, with average daily turnover of 21.7m shares, roughly 1.58% below its median, so the decline did not come with unusually heavy selling. ## Key Events This week’s story centred on the NHS contract extension, defence momentum, an insider sale, and a security-related probe. Around Tuesday, Palantir’s existing UK NHS engagement was extended by two years, but several MPs questioned what the break clause was actually for, implying the renewal carried weak constraints and that the rivalry could return. On the defence and federal side, Palantir co-hosted a defence AI summit with Ondas and Regna AI, while OLIGO Security secured FedRAMP high-level certification through Palantir’s FedStart programme. Director Alexander D. Moore disclosed the sale of about $2.69m in common shares on 18 November. US authorities also charged a Russian national over an alleged effort to target Palantir workers, a story that recurred from Thursday onward. Across the sector, Anthropic IPO chatter, Nvidia volatility and rate-hike bets rattled tech; Palantir fell in step. The valuation debate over Foundry and AIP deals ran through the week. ## Analyst Ratings A total of 34 institutions cover Palantir: 21 rate it buy, 3 overweight, 8 hold, 1 underweight, and 1 sell. The consensus rating is buy, with a consensus target of $222.90, about 55.34% above the current price of $143.49. The target range is wide, from $80 at the low end to $273 at the high end, pointing to clear disagreement among analysts. Within the application-software industry, Palantir ranks 10th out of 206 names, and coverage is far denser than the sector norm of 10 average or 6 median firms. ## The Week Ahead The next hard catalyst is the fiscal-year 2026 annual results, scheduled for 1 February 2027 after the close, with estimates of $1.6729 EPS and $8.551bn revenue — still too far out to drive next week’s tape. Friday’s after-hours quote recovered to $145.60 versus the $143.49 close, a modest improvement in overnight tone. On the macro side, 24 November brings FHFA house prices, the Case-Shiller 20-city index, consumer confidence and the Richmond Fed composite. Consumer confidence is expected at 92.5 from 91.7 prior; a miss against consensus could shift appetite for tech. For Palantir itself, watch how the post-NHS competitive picture develops, whether the defence AI summit produces further commitments, and whether the stock can stabilise while the valuation debate continues. ## In Short This week set up a visible tension: a still-positive analyst setup, with a consensus target about 55% above spot, alongside NHS continuity and deepening defence and federal traction; against a share price that fell 14.58%, broke below both the 20-day and 60-day moving averages and hit a 60-day low, with the latest session’s large-lot money pointing net seller. Valuation supplies the connective tissue: at roughly 94x earnings, the stock is highly sensitive to any shift in order cadence or rate expectations. The question for February’s annual report is whether defence and enterprise order strength can re-anchor the growth story behind that multiple. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md) - [PTIR.US](https://longbridge.com/en/quote/PTIR.US.md) - [PLTY.US](https://longbridge.com/en/quote/PLTY.US.md) - [PLTU.US](https://longbridge.com/en/quote/PLTU.US.md) - [PLOO.US](https://longbridge.com/en/quote/PLOO.US.md) - [PLTG.US](https://longbridge.com/en/quote/PLTG.US.md) - [PLTD.US](https://longbridge.com/en/quote/PLTD.US.md) - [PLTZ.US](https://longbridge.com/en/quote/PLTZ.US.md) - [PLTW.US](https://longbridge.com/en/quote/PLTW.US.md) ## Related News & Research - [Palantir Technologies (PLTR) Ties Up Defense AI Deal As UK NHS Rivalry Returns](https://longbridge.com/en/news/305865049.md) - [Ondas Co-Hosts Defense AI Summit With Palantir, Regna AI](https://longbridge.com/en/news/306282622.md) - [OLIGO Security Achieves FedRAMP® Class D (High) Certification Through Palantir’s FedStart Program | PLTR Stock News](https://longbridge.com/en/news/306146320.md) - [Palantir's reported billion-dollar government contract and valuation risk](https://longbridge.com/en/news/305569364.md) - [MPs ask what the break clause was for as Palantir wins two more years in the NHS](https://longbridge.com/en/news/305803837.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**